Andersen et al. evaluate the effectiveness and safety of PCSK9 inhibitors, alirocumab, and evolocumab, in a register-based cohort of 907 individuals with dyslipidemia. Their findings show a 49% reduction in LDL-C levels and no significant changes in clinical outcomes following a mandated switch from alirocumab to evolocumab.
- Michael Asger Andersen
- Anne Helms Andreasen
- Tonny Studsgaard Petersen
